Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2016 2
2017 2
2018 1
2019 1
2020 5
2021 9
2022 13
2023 15
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

46 results

Results by year

Filters applied: . Clear all
Page 1
Case report: Olverembatinib monotherapy: the chemotherapy-free regimen for an elderly patient with relapsed Ph-positive acute lymphoblastic leukemia.
Ding J, Li W. Ding J, et al. Front Pharmacol. 2023 Nov 16;14:1320641. doi: 10.3389/fphar.2023.1320641. eCollection 2023. Front Pharmacol. 2023. PMID: 38035030 Free PMC article.
Thus, third-generation BCR/ABL1 TKIs, including ponatinib and olverembatinib, have been developed with the aim of overcoming drug resistance. ...Conclusion: For elderly patients with relapsed Ph(+)-ALL, olverembatinib monotherapy may offer a novel option with a good …
Thus, third-generation BCR/ABL1 TKIs, including ponatinib and olverembatinib, have been developed with the aim of overcoming drug res …
Olverembatinib combined with blinatumomab in treating T315I-mutated Philadelphia chromosome-positive acute lymphoblastic leukemia: two-case report.
Fan S, Wang L, Lu Y, Li Z. Fan S, et al. Ann Hematol. 2024 Feb;103(2):525-532. doi: 10.1007/s00277-023-05519-5. Epub 2023 Nov 9. Ann Hematol. 2024. PMID: 37940719
However, diseases with ABL kinase domain mutation T315I are resistant to the majority of TKIs, which is responsible for treatment failure. Olverembatinib is a third-generation TKI that has been approved for the treatment of T315I-mutated chronic myeloid leukemia (CML) in C …
However, diseases with ABL kinase domain mutation T315I are resistant to the majority of TKIs, which is responsible for treatment failure. …
Asciminib in the Treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia: Focus on Patient Selection and Outcomes.
Hijiya N, Mauro MJ. Hijiya N, et al. Cancer Manag Res. 2023 Aug 23;15:873-891. doi: 10.2147/CMAR.S353374. eCollection 2023. Cancer Manag Res. 2023. PMID: 37641687 Free PMC article. Review.
In particular, the only previously available treatments for patients with CML-CP with the T315I mutation were ponatinib, olverembatinib (exclusively approved for use in China at the time of this writing), omacetaxine, and hematopoietic stem cell transplantation. ...
In particular, the only previously available treatments for patients with CML-CP with the T315I mutation were ponatinib, olverembatinib …
Olverembatinib Treatment in Pediatric Patients With Relapsed Philadelphia-Chromosome-Positive Acute Lymphoblastic Leukemia.
Li X, Zhang J, Liu F, Liu T, Zhang R, Chen Y, Guo Y, Fang Y, Xu X, Pui CH, Zhu X. Li X, et al. Clin Lymphoma Myeloma Leuk. 2023 Sep;23(9):660-666. doi: 10.1016/j.clml.2023.04.012. Epub 2023 May 11. Clin Lymphoma Myeloma Leuk. 2023. PMID: 37301632 Review.
The median duration of olverembatinib treatment was 70 days (range: 4-340) and the median cumulative dose was 600 mg (range: 80-3810). ...Safety profile in 6 evaluable patients was excellent with grade 2 extremity pain occurred in 2 patients and grade 2 myopathy of lower e …
The median duration of olverembatinib treatment was 70 days (range: 4-340) and the median cumulative dose was 600 mg (range: 80-3810) …
Management of chronic myeloid leukemia in 2023 - common ground and common sense.
Senapati J, Sasaki K, Issa GC, Lipton JH, Radich JP, Jabbour E, Kantarjian HM. Senapati J, et al. Blood Cancer J. 2023 Apr 24;13(1):58. doi: 10.1038/s41408-023-00823-9. Blood Cancer J. 2023. PMID: 37088793 Free PMC article. Review.
Asciminib is a third-generation TKI with possibly a better toxicity profile, but lesser activity in T315I-mutated CML. Olverembatinib is another potent third-generation TKI with early promising results....
Asciminib is a third-generation TKI with possibly a better toxicity profile, but lesser activity in T315I-mutated CML. Olverembatinib …
46 results